IDEXX Q1 EPS $2.96 (+5%), rev $998M (+4%); raises FY25 revenue & EPS outlook

IDEXX LABORATORIES INC /DE

2025-Q1 EPS reported $2.96 revenue$998,427,000

Q1 revenue $998M (+4% reported, +5% organic); EPS $2.96 (+5%, +7% comparable).
CAG Diagnostics recurring revenue +3% reported, +4.5% organic; VetLab consumables organic +10%.
Launched IDEXX Cancer Dx for early canine lymphoma detection in North American reference labs.
FY25 revenue guidance raised to $4,095M-$4,210M; EPS guidance raised to $11.93-$12.43 ($0.19 increase).
FY25 organic revenue growth outlook maintained at 6%-9%; comparable EPS growth maintained at 8%-12%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.